BioAge Labs, Inc.
BIOANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | |
|---|---|---|---|
| Revenue | $9.0M | $0 | — |
| Operating income | −$92.8M | −$78.2M | −$48.4M |
| Net income | −$80.6M | −$71.1M | −$63.9M |
| Total assets | $294.9M | $358.2M | $25.9M |
| Total liabilities | $22.8M | $35.1M | $66.6M |
| Equity | $272.1M | $323.1M | −$173.4M |
| EPS (diluted) | $-2.24 | $-6.63 | $-38.17 |
| Shares out. | 35.9M | 35.9M | 1.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1031.5%
- Net margin
- −896.1%
- Return on equity
- −29.6%
- Return on assets
- −27.3%
- Return on capital (ROCE)
- −33.8%
- Liabilities / assets
- 7.7%
- Debt / equity
- 0.08×
- Book value / share
- $7.59
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 12.64safe
- Accruals / assets
- 0.3%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Khosla Ventures Vi, L.P.Passive (13G)May 15, 2026
- Cormorant Asset Management, LpPassive (13G)May 15, 2026
- Blackrock, Inc.Passive (13G)Apr 27, 2026
- Adar1 Capital Management, LlcPassive (13G)Feb 17, 2026
- Fortney KristenPassive (13G)Feb 13, 2026
- Ra Capital Management, L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Goldstein Dov A MdOfficer — Chief Financial Officer | Apr 23, 2026 | Option exercise | 3,542 | $4.38 |
| Rubin Paul DOfficer — Chief Medical Officer | Apr 1, 2026 | Option exercise | 5,437 | $4.11 |
| Rubin Paul DOfficer — Chief Medical Officer | Mar 2, 2026 | Option exercise | 5,433 | $4.11 |
| Goldstein Dov A MdOfficer — Chief Financial Officer | Mar 1, 2026 | Option exercise | 3,542 | $4.38 |
| Rubin Paul DOfficer — Chief Medical Officer | Feb 2, 2026 | Option exercise | 5,433 | $4.11 |
| Goldstein Dov A MdOfficer — Chief Financial Officer | Feb 1, 2026 | Option exercise | 3,541 | $4.38 |
| Goldstein Dov A MdOfficer — Chief Financial Officer | Jan 16, 2026 | Option exercise | 3,542 | $4.38 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 4.6 | -9.3% |
| Apr 30, 2026 | 1.9M | 4.4 | +8.0% |
| Apr 15, 2026 | 1.7M | 5.2 | +11.9% |
| Mar 31, 2026 | 1.6M | 2.3 | +15.5% |
| Mar 13, 2026 | 1.4M | 2.6 | +5.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 8, 2026
- Results of operations · Regulation FD disclosureMar 24, 2026
- Entered a material agreement · Regulation FD disclosureJan 22, 2026
- Regulation FD disclosure · Other material eventJan 20, 2026
- Regulation FD disclosure · Other material eventJan 12, 2026
- Regulation FD disclosure · Other material eventDec 4, 2025
- Results of operationsNov 6, 2025
- Results of operationsAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 8-KMay 8, 2026
- 10-QMay 8, 2026
- SCHEDULE 13GApr 27, 2026
- 4Apr 24, 2026
- ARSApr 21, 2026
- DEFA14AApr 21, 2026
- DEF 14AApr 21, 2026
- 4Apr 3, 2026
- 144Apr 1, 2026
- S-3ASRMar 24, 2026
- S-8Mar 24, 2026
- 10-KMar 24, 2026
- 8-KMar 24, 2026